Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopic treatment of upper urinary tract neoplasia with fluorescence-guided follow-up
2014-000669-39Phase 3Terminated
- Sponsor
- Gregers Gautier Hermann
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 5-aminolevulinic acid in Renal pelvis urothelial carcinoma (UTUC) and upper tract urothelial carcinoma (UTUC), sponsored by Gregers Gautier Hermann. Primary endpoint: Tumor presence at 4-month follow-up nephro-ureteroscopy. Started Apr 2014; status: terminated.
02
Drugs
5-aminolevulinic acid
03
Conditions
Renal pelvis urothelial carcinoma (UTUC)upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2014-000669-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000669-39.